ESTRO 2024 - Abstract Book

S2340

Clinical - Urology

ESTRO 2024

total of 12 patients experienced late grade 3 genitourinary toxicity (crude rate 4.4%), while two patients had late grade 3 gastro-intestinal toxicity (0.7%). IPSS increased during the first months from minor to moderate symptoms: median score increase of 6 (IQR 3-10) to 9 (IQR 6-15); p<0.0001. IPSS remained stable around 8 during subsequent follow-up. Bowel complaints transiently increased from 6 months to 1.5 years from minor bother in 3% to maximally 9% at 9 months (p=0.001). Complete erectile dysfunction increased from 39 (14%) to 88 (32%) patients (p<0.0001) in the first month and stayed relatively stable thereafter (Figure 2 for toxicity scores over time).

Conclusion: